Skip to main content

Nurix Therapeutics, Inc 8-K, filed Nov 3, 2026

Nurix Therapeutics, Inc. (NRIX)

8-K 2026-11-03 For: 2026-11-03
View Original
Added on November 03, 2026

About this 8-K

Nurix Therapeutics, Inc filed this 8-K on November 3, 2026.

On November 3, 2026, Nurix Therapeutics, Inc. said Sanofi S.A. will discontinue the Phase 1 first-in-human trial of SAR448272 and terminate the program, eliminating expected future development, regulatory and commercial milestone payments and royalties. AI summary

Items reported

  • Item 8.01: Other events